| | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H32N6 |
| Molar mass | 452.606 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Tribendimidine is a broad-spectrum anthelmintic agent developed in China, at the National Institute of Parasitic Diseases in Shanghai. It is a derivative of amidantel. [1]
In clinical trials, it was highly effective in treating ankylostomiasis, ascariasis and enterobiasis. [2] It is also effective against clonorchiasis. [3] However, animal studies suggest it is ineffective in treating Schistosoma mansoni or Fasciola hepatica disease. [1] The drug has also performed well in trials against opisthorchiasis, curing about 70% of cases. [4]
Tribendimidine is manufactured by Shandong Xinhua Pharmaceutical Company Limited in Zibo, Shandong, China. It was approved by the China Food and Drug Administration in 2007.[ citation needed ]